Companies › Servier
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Vorasidenib (S095032) IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1, IDH2 | Phase 3 | Residual or Recurrent Grade 2 IDH Mutant Glioma | Oct 2030 |
| Ivosidenib Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 2 | Cholangiocarcinoma Non-resectable | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06081829 | Ivosidenib | Phase 2 | Cholangiocarcinoma Non-resectable | Oncology | May 2027 |
| NCT06780930 | Vorasidenib (S095032) | Phase 3 | Residual or Recurrent Grade 2 IDH Mutant Glioma | Oncology | Oct 2030 |
Institut de Recherches Internationales Servier (I.R.I.S.) Servier Affaires Médicales Nuvation Bio Biokin (Shanghai) Biopharmaceutical Aura Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.